Natixis Advisors LLC Has $2.87 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Natixis Advisors LLC lessened its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 34.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 209,328 shares of the company's stock after selling 110,685 shares during the quarter. Natixis Advisors LLC owned approximately 0.23% of Myriad Genetics worth $2,870,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of MYGN. Point72 Hong Kong Ltd bought a new position in Myriad Genetics during the 3rd quarter worth approximately $32,000. KBC Group NV increased its holdings in shares of Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company's stock valued at $80,000 after acquiring an additional 3,334 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Myriad Genetics by 43.8% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock valued at $132,000 after acquiring an additional 1,471 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at approximately $153,000. Finally, Inspire Advisors LLC lifted its stake in Myriad Genetics by 48.1% during the fourth quarter. Inspire Advisors LLC now owns 11,226 shares of the company's stock worth $154,000 after purchasing an additional 3,644 shares during the last quarter. Institutional investors own 99.02% of the company's stock.

Myriad Genetics Stock Performance

MYGN stock traded up $0.01 during trading on Thursday, reaching $9.22. 678,586 shares of the company's stock were exchanged, compared to its average volume of 851,700. Myriad Genetics, Inc. has a 1-year low of $9.19 and a 1-year high of $29.30. The firm has a market cap of $841.87 million, a PE ratio of -7.09 and a beta of 1.79. The company's fifty day moving average price is $11.89 and its 200-day moving average price is $16.75. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). The company had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period in the previous year, the company earned ($0.12) EPS. On average, research analysts expect that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on MYGN. UBS Group lowered their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, February 25th. Bank of America lowered their price objective on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating for the company in a research report on Monday, March 3rd. Leerink Partnrs cut shares of Myriad Genetics from a "strong-buy" rating to a "hold" rating in a report on Monday, December 9th. Craig Hallum began coverage on Myriad Genetics in a research note on Wednesday, February 12th. They issued a "buy" rating and a $29.00 target price for the company. Finally, Piper Sandler upgraded Myriad Genetics from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $11.50 to $12.50 in a research report on Wednesday, March 12th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Myriad Genetics presently has an average rating of "Hold" and a consensus price target of $21.89.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.